CRISPR Therapeutics AG (CRSP): Price and Financial Metrics


CRISPR Therapeutics AG (CRSP): $57.05

1.82 (+3.30%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add CRSP to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

CRSP POWR Grades


  • CRSP scores best on the Value dimension, with a Value rank ahead of 80.73% of US stocks.
  • CRSP's strongest trending metric is Quality; it's been moving down over the last 179 days.
  • CRSP ranks lowest in Stability; there it ranks in the 3rd percentile.

CRSP Stock Summary

  • Of note is the ratio of CRISPR Therapeutics AG's sales and general administrative expense to its total operating expenses; merely 7.35% of US stocks have a lower such ratio.
  • With a year-over-year growth in debt of 266.32%, CRISPR Therapeutics AG's debt growth rate surpasses 95.46% of about US stocks.
  • Revenue growth over the past 12 months for CRISPR Therapeutics AG comes in at 127,154.9%, a number that bests 99.98% of the US stocks we're tracking.
  • If you're looking for stocks that are quantitatively similar to CRISPR Therapeutics AG, a group of peers worth examining would be ETON, VTVT, BEAM, LPCN, and PLXP.
  • Visit CRSP's SEC page to see the company's official filings. To visit the company's web site, go to www.crisprtx.com.

CRSP Valuation Summary

  • CRSP's EV/EBIT ratio is 17.8; this is 39.25% lower than that of the median Healthcare stock.
  • Over the past 59 months, CRSP's EV/EBIT ratio has gone up 26.5.
  • Over the past 59 months, CRSP's EV/EBIT ratio has gone up 26.5.

Below are key valuation metrics over time for CRSP.

Stock Date P/S P/B P/E EV/EBIT
CRSP 2021-08-31 10.6 3.7 21.3 17.8
CRSP 2021-08-30 10.2 3.5 20.6 17.1
CRSP 2021-08-27 10.5 3.6 21.1 17.6
CRSP 2021-08-26 10.3 3.6 20.8 17.3
CRSP 2021-08-25 10.6 3.7 21.5 18.0
CRSP 2021-08-24 10.7 3.7 21.6 18.1

CRSP's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • CRSP has a Quality Grade of C, ranking ahead of 73.06% of graded US stocks.
  • CRSP's asset turnover comes in at 0.441 -- ranking 101st of 681 Pharmaceutical Products stocks.
  • CDTX, NVS, and SEEL are the stocks whose asset turnover ratios are most correlated with CRSP.

The table below shows CRSP's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.441 1 0.579
2021-03-31 0.001 1 -0.839
2020-12-31 0.001 1 -1.179
2020-09-30 0.067 1 -1.230
2020-06-30 0.301 1 0.242
2020-03-31 0.352 1 0.539

CRSP Price Target

For more insight on analysts targets of CRSP, see our CRSP price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $162.94 Average Broker Recommendation 1.55 (Moderate Buy)

CRSP Stock Price Chart Interactive Chart >

Price chart for CRSP

CRSP Price/Volume Stats

Current price $57.05 52-week high $169.76
Prev. close $55.23 52-week low $42.51
Day low $54.49 Volume 350,662
Day high $57.54 Avg. volume 1,504,668
50-day MA $57.71 Dividend yield N/A
200-day MA $79.03 Market Cap 4.42B

CRISPR Therapeutics AG (CRSP) Company Bio


CRISPR Therapeutics AG focuses on the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 gene-editing platform. The company is based in Basel, Switzerland.


CRSP Latest News Stream


Event/Time News Detail
Loading, please wait...

CRSP Latest Social Stream


Loading social stream, please wait...

View Full CRSP Social Stream

Latest CRSP News From Around the Web

Below are the latest news stories about CRISPR Therapeutics AG that investors may wish to consider to help them evaluate CRSP as an investment opportunity.

Peloton Isn’t the ONLY Takeover Target. What Companies Could Be Bought Out in 2022?

Savvy investors can generate lucrative returns by investing in companies that look like prime takeover targets.

Tezcan Gecgil on InvestorPlace | February 23, 2022

Why Jim Cramer Believes Sirius XM Is Inexpensive

On CNBCs "Mad Money Lightning Round," Jim Cramer said CRISPR Therapeutics AG (NASDAQ: CRSP ) is likely to "lose a lot of money. But more importantly, this is the kind of company right now that is so out of favor that, unless you are willing to take a beating, which I do not encourage, I think you have to take a pass on it," With American Airlines Group Full story available on Benzinga.com

Benzinga | February 23, 2022

10 Genomics Stocks in Cathie Wood’s Portfolio That Are Underperforming

In this article, we discuss 10 genomics stocks in Cathie Wood’s portfolio that are underperforming. If you want to skip our detailed analysis of these stocks, go directly to 5 Genomics Stocks in Cathie Wood’s Portfolio That Are Underperforming. ARK Investment Management is an innovation-focused hedge fund that is headquartered in St. Petersburg, Florida, with […]

Yahoo | February 23, 2022

CRISPR Therapeutics AG (NASDAQ:CRSP) Shares Could Be 29% Below Their Intrinsic Value Estimate

In this article we are going to estimate the intrinsic value of CRISPR Therapeutics AG ( NASDAQ:CRSP ) by estimating...

Yahoo | February 18, 2022

Needham Thinks Crispr Therapeutics AG’s Stock is Going to Recover

Needham analyst Gil Blum maintained a Buy rating on Crispr Therapeutics AG (CRSP – Research Report) today and set a price target of $170.00. The company's shares closed last Tuesday at $60.97, close to its 52-week low of $55.35. According to TipRanks.com, Blum 's ranking currently consits of 0 on a 0-5 ranking scale, with an average return of -38.5% and a 7.7% success rate. Blum covers the Healthcare sector, focusing on stocks such as Mereo Biopharma Group Plc, Aeglea Biotherapeutics, and Rocket Pharmaceuticals. The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Crispr Therapeutics AG with a $146.

Howard Kim on TipRanks | February 16, 2022

Read More 'CRSP' Stories Here

CRSP Price Returns

1-mo 9.80%
3-mo -4.49%
6-mo -27.59%
1-year -51.82%
3-year 55.36%
5-year 279.32%
YTD -24.72%
2021 -50.51%
2020 151.39%
2019 113.18%
2018 21.68%
2017 15.89%

Continue Researching CRSP

Here are a few links from around the web to help you further your research on CRISPR Therapeutics AG's stock as an investment opportunity:

CRISPR Therapeutics AG (CRSP) Stock Price | Nasdaq
CRISPR Therapeutics AG (CRSP) Stock Quote, History and News - Yahoo Finance
CRISPR Therapeutics AG (CRSP) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.7716 seconds.